SCHEMBL6017934

SCHEMBL6017934

COc1cccc(OC)c1-c1nc(C(=O)NCc2ccc(C)c(C)c2)c(O)c(=O)n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
KCNE1 P15382 1/20 0.45
CCR1 P32246 1/20 0.45
KCNQ1 P51787 1/20 0.45
ADORA2A P29274 4/20 0.43
ALDH1A1 P00352 3/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CRHR1 P34998 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
GAA P10253 1/20 0.41
TACR1 P25103 1/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017926 0.92 TSHR (0.44) TSHRKCNE1CCR1KCNQ1ADORA2A
SCHEMBL6882315 0.90 ADORA2A (0.42) TSHRKCNE1CCR1KCNQ1ADORA2A
SCHEMBL6018060 0.90 TSHR (0.47) TSHRKCNE1CCR1KCNQ1ADORA2A
SCHEMBL6017677 0.89 LMNA (0.48) TSHRKCNE1CCR1KCNQ1ADORA2A
SCHEMBL6018704 0.88 KCNE1 (0.56) KCNE1CCR1KCNQ1ADORA2AALDH1A1
SCHEMBL6017737 0.86 KCNE1 (0.44) KCNE1CCR1KCNQ1ADORA2ASMN1; SMN2
SCHEMBL6017668 0.85 MEN1 (0.47) ALDH1A1MAPTHPGDSMN1; SMN2MEN1
SCHEMBL6018601 0.84 TP53 (0.51) ALDH1A1HTTMAPTSMN1; SMN2MEN1
SCHEMBL6017795 0.84 MMP1 (0.50) KCNE1CCR1KCNQ1ALDH1A1MEN1
SCHEMBL6018089 0.81 TSHR (0.45) TSHRKCNE1CCR1KCNQ1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US claimed
US-7037908-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-02 US disclosed
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY 2004-11-18 US disclosed
WO-2004096128-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229892-A1 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex DUT, CDK6, TYMS TSHR 4295/4885KCNE1 3647/4885CCR1 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.